The Dopamine Foundry

Parkinson’s neuron replacement today costs $150,000–$300,000 per patient. We aim to change that. The Dopamine Foundry is an ambitious project designed to create a self-sustaining, allogeneic iPSC manufacturing platform producing ready-to-implant midbrain A9 dopamine neurons at insulin-level pricing — $500–$1,000 per dose by 2030. Currently in the planning stage, we’re seeking funding through innovative channels like VOLT sales to make this vision a reality. No delays, no compromises — just scalable brain repair for millions.

The process begins with a single, HLA-homozygous donor whose skin cells are reprogrammed into a master iPSC line and cryopreserved in a GMP bank capable of generating billions of doses. From this universal bank, cells are thawed and expanded in fully automated, closed-system 1,000-liter perfusion bioreactors using microcarrier-free 3D culture to produce midbrain A9 dopaminergic progenitors at 95% purity. AI-driven in-line monitoring optimizes yield and potency in real time, while robotic fill/finish systems aliquot 1–2 million viable neurons per cryovial under strict GMP conditions. Quality control—including sterility, karyotyping, and dopamine-release assays—occurs automatically within the production loop. Finished doses are packaged in LN2-free VIA Capsule shippers and delivered within 48 hours to partner hospitals worldwide, where surgeons use CT-guided frameless stereotaxy (or robotic ROSA systems) to implant the cells bilaterally into the putamen—even in MRI-incompatible patients with metal implants—achieving ±1.2 mm accuracy and restoring natural dopamine production within 6–12 months.